0QF Stock Overview
A biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Moderna, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$184.33 |
| 52 Week High | US$0 |
| 52 Week Low | US$0 |
| Beta | 1.7 |
| 11 Month Change | 0% |
| 3 Month Change | 10.98% |
| 1 Year Change | 40.56% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 52.51% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0QF | CH Biotechs | CH Market | |
|---|---|---|---|
| 7D | 0% | -1.4% | 0.6% |
| 1Y | 40.6% | 105.2% | 5.8% |
Return vs Industry: 0QF exceeded the Swiss Biotechs industry which returned -24.8% over the past year.
Return vs Market: 0QF exceeded the Swiss Market which returned -0.9% over the past year.
Price Volatility
| 0QF volatility | |
|---|---|
| 0QF Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 12.7% |
| Market Average Movement | 3.3% |
| 10% most volatile stocks in CH Market | 6.6% |
| 10% least volatile stocks in CH Market | 1.6% |
Stable Share Price: 0QF has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 0QF's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 3,900 | Stephane Bancel | www.modernatx.com |
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella-zoster virus, and human immunodeficiency virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics.
Moderna, Inc. Fundamentals Summary
| 0QF fundamental statistics | |
|---|---|
| Market cap | CHF 49.23b |
| Earnings (TTM) | CHF 7.70b |
| Revenue (TTM) | CHF 17.75b |
6.4x
P/E Ratio2.8x
P/S RatioIs 0QF overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0QF income statement (TTM) | |
|---|---|
| Revenue | US$19.26b |
| Cost of Revenue | US$8.71b |
| Gross Profit | US$10.55b |
| Other Expenses | US$2.19b |
| Earnings | US$8.36b |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 21.64 |
| Gross Margin | 54.78% |
| Net Profit Margin | 43.41% |
| Debt/Equity Ratio | 0% |
How did 0QF perform over the long term?
See historical performance and comparison